Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Undruggable proteins are a class of proteins that are often characterized by large, complex
structures or functions that are difficult to interfere with using conventional drug design …
structures or functions that are difficult to interfere with using conventional drug design …
Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia
H Inaba, CH Pui - Journal of clinical medicine, 2021 - mdpi.com
The outcomes of pediatric acute lymphoblastic leukemia (ALL) have improved remarkably
during the last five decades. Such improvements were made possible by the incorporation of …
during the last five decades. Such improvements were made possible by the incorporation of …
The genetics and mechanisms of T cell acute lymphoblastic leukaemia
L Belver, A Ferrando - Nature Reviews Cancer, 2016 - nature.com
T cell acute lymphoblastic leukaemia (T-ALL) is an aggressive haematological malignancy
derived from early T cell progenitors. In recent years genomic and transcriptomic studies …
derived from early T cell progenitors. In recent years genomic and transcriptomic studies …
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia
Deregulation of the BCL2 gene family plays an important role in the pathogenesis of acute
myeloid leukemia (AML). A BCL2 inhibitor, venetoclax, has received approval from the US …
myeloid leukemia (AML). A BCL2 inhibitor, venetoclax, has received approval from the US …
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype
N Jain, AV Lamb, S O'Brien, F Ravandi… - Blood, The Journal …, 2016 - ashpublications.org
Early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL/LBL) is a recently
recognized high-risk T lymphoblastic leukemia/lymphoma (T-ALL/LBL) subgroup. The …
recognized high-risk T lymphoblastic leukemia/lymphoma (T-ALL/LBL) subgroup. The …
MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint
BAH Smith, A Deutzmann, KM Correa… - Proceedings of the …, 2023 - National Acad Sciences
The Siglecs (sialic acid-binding immunoglobulin-like lectins) are glycoimmune checkpoint
receptors that suppress immune cell activation upon engagement of cognate sialoglycan …
receptors that suppress immune cell activation upon engagement of cognate sialoglycan …
Precision medicine in acute lymphoblastic leukemia
CH Pui - Frontiers of medicine, 2020 - Springer
The cure rate of childhood acute lymphoblastic leukemia (ALL) has exceeded 90% in some
contemporary clinical trials. However, the dose intensity of conventional chemotherapy has …
contemporary clinical trials. However, the dose intensity of conventional chemotherapy has …
The role of IL-7 and IL-7R in cancer pathophysiology and immunotherapy
C Wang, L Kong, S Kim, S Lee, S Oh, S Jo… - International journal of …, 2022 - mdpi.com
Interleukin-7 (IL-7) is a multipotent cytokine that maintains the homeostasis of the immune
system. IL-7 plays a vital role in T-cell development, proliferation, and differentiation, as well …
system. IL-7 plays a vital role in T-cell development, proliferation, and differentiation, as well …
Bax/Bcl-2 cascade is regulated by the EGFR pathway: therapeutic targeting of non-small cell lung cancer
Non-small cell lung carcinoma (NSCLC) comprises 80%–85% of lung cancer cases. EGFR
is involved in several cancer developments, including NSCLC. The EGFR pathway …
is involved in several cancer developments, including NSCLC. The EGFR pathway …
T-cell acute lymphoblastic leukemia: a roadmap to targeted therapies
V Cordo', JCG van der Zwet, K Canté-Barrett… - Blood cancer …, 2021 - AACR
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy
characterized by aberrant proliferation of immature thymocytes. Despite an overall survival …
characterized by aberrant proliferation of immature thymocytes. Despite an overall survival …